Praxis Precision Medicines, Inc. PRAX

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001689548

None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $937.9M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, thin data, degenerate inputs not computable: fortress balance sheet
Inputs computable	5 of 13
Graded from	filings received through Feb 19, 2026 272 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026
Last close	$305.16 2026-11-17; market equity $8.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 19, 2026

We are a fully integrated, leading central nervous system, or CNS, precision neuroscience biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and both rare and more prevalent neurological disorders.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 51.4						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(7.6%)	(6.7%)		51.4	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 11.7						
Altman Z double-prime	12.98	0.31		6.7	705	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(3.61x)				
one or more required annual facts are missing						
Current ratio	10.22x	2.68x		16.8	781	2025-12-31
Growth and financing, sleeve percentile 37.3						
Revenue growth, three-year compound	not computable	9.6%				
four annual observations are required; found 3						
Free cash flow growth, three-year compound	not computable	11.1%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	33.9%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	101.2%	3.2%		2.4	663	2025-12-31
Net share issuance, one year	38.1%	1.6%		72.1	625	2026-02-16

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 38.1%
Thin data	5 of 13 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-17 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	46.5%	(1.7%)	78
Distance from 52-week high	(21.0%)	(30.5%)	60
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(2.9%)	0.5%	37
Book value to price	0.15	0.28	32
Sales to price	0.00	0.36	0
Composite equity issuance, five years	238.6%	13.5%	94
Relative strength against the sector, log excess return	0.21	(0.19)	78
Twelve-month failure probability, CHS model	0.05%	0.06%	45

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$361.9M
Operating cash flow, four quarters	-$321.8M
Months of runway	13.5
Days since last periodic filing	9 (10-Q received Nov 9, 2026)
Median daily dollar volume, 63 sessions	$127.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$303.3M	2025-12-31	2026-02-19	10-K	26-000029
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$249.1M	2025-12-31	2026-02-19	10-K	26-000029
3	assets	us-gaap:Assets	$937.9M	2025-12-31	2026-02-19	10-K	26-000029
4	assets	us-gaap:Assets	$483.1M	2024-12-31	2026-02-19	10-K	26-000029
5	current assets	us-gaap:AssetsCurrent	$610.9M	2025-12-31	2026-02-19	10-K	26-000029
6	current liabilities	us-gaap:LiabilitiesCurrent	$59.8M	2025-12-31	2026-02-19	10-K	26-000029
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.1B	2025-12-31	2026-02-19	10-K	26-000029
8	operating income	us-gaap:OperatingIncomeLoss	-$326.2M	2025-12-31	2026-02-19	10-K	26-000029
9	book equity	us-gaap:StockholdersEquity	$878.1M	2025-12-31	2026-02-19	10-K	26-000029
10	liabilities	us-gaap:Liabilities	$59.8M	2025-12-31	2026-02-19	10-K	26-000029
11	revenue	us-gaap:Revenues	$0	2025-12-31	2026-02-19	10-K	26-000029
12	revenue	us-gaap:Revenues	$8.6M	2024-12-31	2026-02-19	10-K	26-000029
13	revenue	us-gaap:Revenues	$2.4M	2023-12-31	2026-02-19	10-K	26-000029
14	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$56,000	2025-12-31	2026-02-19	10-K	26-000029
15	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$131.8M	2024-12-31	2026-02-19	10-K	26-000029
16	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$0	2024-12-31	2026-02-19	10-K	26-000029
17	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$111.1M	2023-12-31	2026-02-19	10-K	26-000029
18	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$50,000	2023-12-31	2026-02-19	10-K	26-000029
19	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$185.0M	2022-12-31	2024-03-05	10-K	24-000034
20	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$444,000	2022-12-31	2024-03-05	10-K	24-000034
21	depreciation amortization	us-gaap:Depreciation	$140,000	2025-12-31	2026-02-19	10-K	26-000029
22	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$302.8M	2025-12-31	2026-02-19	10-K	26-000029
23	income tax	us-gaap:IncomeTaxExpenseBenefit	$471,000	2025-12-31	2026-02-19	10-K	26-000029
24	current assets	us-gaap:AssetsCurrent	$404.4M	2024-12-31	2026-02-19	10-K	26-000029
25	current liabilities	us-gaap:LiabilitiesCurrent	$37.5M	2024-12-31	2026-02-19	10-K	26-000029
26	assets	us-gaap:Assets	$87.9M	2023-12-31	2025-02-28	10-K	25-000040
27	assets	us-gaap:Assets	$115.1M	2022-12-31	2024-03-05	10-K	24-000034
28	shares outstanding	dei:EntityCommonStockSharesOutstanding	27,850,833	2026-02-16	2026-02-19	10-K	26-000029
29	shares outstanding	dei:EntityCommonStockSharesOutstanding	20,163,250	2025-02-26	2025-02-28	10-K	25-000040

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.